Eli Lilly and Company discovers develops and markets human pharmaceuticals in the United States Europe China Japan and internationally. The company offers Basaglar Humalog Humalog Mix 75/25 Humalog U-100 Humalog U-200 Humalog Mix 50/50 insulin lispro insulin lispro protamine insulin lispro mix 75/25 Humulin Humulin 70/30 Humulin N Humulin R and Humulin U-500 for diabetes; Jardiance Mounjaro and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products including Alimta Cyramza Erbitux Jaypirca Retevmo Tyvyt and Verzenio. In addition the company offers Olumiant for rheumatoid arthritis atopic dermatitis severe alopecia areata and COVID-19; Taltz for plaque psoriasis psoriatic arthritis ankylosing spondylitis and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder diabetic peripheral neuropathic pain generalized anxiety disorder fibromyalgia and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd and Genentech Inc.; Biologics Inc. AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co. Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis Indiana.